This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Conflicting studies in recent years report that genetic or pharmacological increases or decreases in ghrelin either increase or have no effect on islet size. Both germline and conditional ghrelin-knockout mice associated with increased islet size, which was further exacerbated by older age and diet-induced obesity.
From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving. Risk Factor Management: Controlling risk factors such as hypertension, diabetes, obesity, and sleep apnea is essential in managing AFib.
From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving. Risk Factor Management: Controlling risk factors such as hypertension, diabetes, obesity, and sleep apnea is essential in managing AFib.
Cardiometabolic diseases, encompassing cardiovascular conditions and metabolic disorders like diabetes, are among the most widespread global health challenges. Pharmacological Interventions : Use of antihypertensive medications, lipid-lowering agents, and antidiabetic drugs.
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] I think we live in a very exciting time right now for those who work in diabetes and cardiovascular disease.
Results revealed that women are twice as likely to exhibit myocardial ischemia in response to mental stress compared to traditional stressors like exercise or pharmacologic stress. Combining behavioral and pharmacological treatment is most effective. Moreover, women under 50 years old are four times more likely to experience MSIMI.
Risk factors for PAD include smoking; having Type 1 or Type 2 diabetes, high blood pressure, high cholesterol, chronic kidney disease, atherosclerosis in other parts of the body (such as coronary artery disease); and being age 75 years or older. and Global Data From the American Heart Association.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content